Citations

Showing 10 of 108104 citations.

Trends in Chronic Liver Disease-Related Hospitalizations: A Population-Based Study
Hall, Lauren , Hagan, Michael , Sharma, Sushma, Yeramaneni, Samrat , Trotter, James F. , Talwalkar, Jayant A., Kanwal, Fasiha , Talwalkar, Jayant, Asrani, Sumeet K. , Hall, Lauren

Mayo Clinic

American Journal of Gastroenterology | October 17, 2018 | Volume: 114 | Issue: 1 | Pages: 98-106

10.1038/s41395-018-0365-4 | PMID 30333543 Get It

OBJECTIVES: In a population-based study, we examined time trends in chronic liver disease (CLD)-related hospitalizations in a large and diverse metroplex. METHODS: We examined all CLD-related inpatient encounters (2000–2015) in Dallas–Fort Worth (DFW) using data from the DFW council collaborative that captures claims data from 97% of all hospitalizations in DFW (10.7 million regional patients). RESULTS: There were 83,539 CLD-related hospitalizations in 48,580 unique patients across 84 hospitals. The age and gender standardized annual rate of CLD-related hospitalization increased from 48.9 per 100,000 in 2000 to 125.7 per 100,000 in 2014. Mean age at hospitalization increased from 54.0 (14.1) to 58.5 (13.5) years; the proportion of CLD patients above 65 years increased from 24.2% to 33.1%. HCV-related hospitalizations plateaued, whereas an increase was seen in hospitalizations related to alcohol (9.1 to 22.7 per 100,000) or fatty liver (1.4 per 100,000 to 19.5 per 100,000). The prevalence of medical comorbidities increased for CLD patients: coronary artery disease (4.8% to 14.3%), obesity (2.8% to 14.6%), chronic kidney disease (2.8% to 18.2%), and diabetes (18.0% to 33.2%). Overall hospitalizations with traditional complications of portal hypertension (ascites, varices, and peritonitis) remained stable over time. However, hospitalization with complications related to infection increased from 54.7% to 66.4%, and renal failure increased by sevenfold (2.7% to 19.5%). CONCLUSIONS: CLD-related hospitalizations have increased twofold over the last decade. Hospitalized CLD patients are older and sicker with multiple chronic conditions. Traditional complications of portal hypertension have been superseded by infection and renal failure, warranting a need to redefine what it means to have decompensated CLD.
Effect of the Head Computed Tomography Choice Decision Aid in Parents of Children With Minor Head Trauma
Homme, James L. , Kharbanda, Anupam B. , Tzimenatos, Leah, Louie, Jeffrey P. , Cohen, Daniel M. , Westphal, Jessica J., Shah, Nilay D. , Inselman, Jonathan , Ferrara, Michael J. , Kuppermann, Nathan , Hess, Erik P. , Nigrovic, Lise E. , Herrin, Jeph , Montori, Víctor M.

Mayo Clinic

JAMA Network Open | October 17, 2018 | Volume: 1 | Issue: 5 | Pages: e182430

10.1001/jamanetworkopen.2018.2430 | PMID 30646167 Get It

Potential Sampling Bias in Investigation of Upright-Supine Test for Vertical Strabismus
Bhatti, M. Tariq

Mayo Clinic

JAMA Ophthalmology | October 17, 2018 | Volume: 136 | Issue: 12 | Pages: 1427

10.1001/jamaophthalmol.2018.4172 | PMID 30326040 Get It

Potential Sampling Bias in Investigation of Upright-Supine Test for Vertical Strabismus—Reply
Eggenberger, Eric , Lemos, João , Lemos, João

Mayo Clinic

JAMA Ophthalmology | October 17, 2018 | Volume: 136 | Issue: 12 | Pages: 1428

10.1001/jamaophthalmol.2018.4178 | PMID 30326037 Get It

Clinical Features Associated with Survival Outcome in African-American Patients with Hepatocellular Carcinoma
Estevez, Jacqueline, Yang, Ju Dong , Leong, Jennifer , Nguyen, Pauline, Giama, Nasra H., Zhang, Ning , Ali, Hamdi A. , Cheung, Ramsey , Roberts, Lewis R. , Schwartz, Myron , Nguyen, Mindie H. , Roberts, Lewis, Roberts, Lewis R , Yang, Ju Dong , Lee, Mei–Hsuan

Mayo Clinic

American Journal of Gastroenterology | October 17, 2018 | Volume: 114 | Issue: 1 | Pages: 80-88

10.1038/s41395-018-0261-y | PMID 30333542 Get It

BACKGROUND: African-Americans (AA) have a higher incidence of hepatocellular carcinoma (HCC) and lower survival. We characterized survival rates and clinical features associated with survival in AA vs. Caucasians with HCC over the past two decades. METHODS: HCC patients from three US medical centers were matched by year of diagnosis (1991–2016): AA ( n = 578)/Caucasian ( n = 578) and placed in one of two groups—HCC diagnosed prior to 2010 or 2010 and after. Data were obtained from chart review and the National Death Index. Multivariate and survival analysis controlling for key predictors were conducted. RESULTS: Prior to 2010, there was no difference in survival between Caucasians and AA ( p = 0.61). After 2010, AA patients had poorer survival compared to Caucasians (35% vs. 44%, respectively, p = 0.044). Over time, survival improved for Caucasians (32% before 2010 vs. 44% after 2010, p = 0.003), but not AA (36% vs. 35%, p = 0.50). AA on presentation (in the after 2010 cohort) were more likely to have BCLC (Barcelona Clinic Liver Cancer) stage C (24% vs. 15%, p = 0.010) and less likely to receive treatment (85% vs. 93%, p = 0.002) compared to matched Caucasians. BCLC beyond stage A (aHR: 1.75, 95% CI: 1.26–2.43, p = 0.001) and child’s class C (aHR 2.05, 95% CI: 1.23–3.41, p = 0.006) were the strongest predictors of mortality, while race was not. CONCLUSIONS: African-Americans presented with more advanced HCC and had poorer survival compared to Caucasians after 2010. Tumor stage was an independent predictor of mortality, but ethnicity was not. Further efforts are needed to improve early HCC diagnosis for AA.
Use of absolute risk measurements in observational dermatology studies: important information for decision‐making is frequently absent
Tjahjono, Leonardo , Cline, Abigail , Huang, Weiqiang , Feldman, Steven R. , Tjahjono, L A , Feldman, S R , Huang, W.W.

Mayo Clinic

British Journal of Dermatology | October 17, 2018 | Volume: 180 | Issue: 3 | Pages: 678-679

10.1111/bjd.17266 | PMID 30328103 Get It

Naïve/memory T‐cell phenotypes in leukemic cutaneous T‐cell lymphoma: Putative cell of origin overlaps disease classification
Sokol, Lubomir , Shao, Haipeng , Horna, Pedro , Shao, Haipeng , Moscinski, Lynn C. , Sokol, Lubomir

Mayo Clinic

Cytometry Part B: Clinical Cytometry | October 17, 2018 | Volume: 96 | Issue: 3 | Pages: 234-241

10.1002/cyto.b.21738 | PMID 30328260 Get It

BackgroundMycosis fungoides (MF) and Sézary Syndrome (SS) are clinically distinct cutaneous T‐cell lymphomas with strikingly similar morphologic and phenotypic features. Prior studies have suggested phenotypic differences based on markers of antigen experience, suggesting a different cell of origin.MethodsSeventy‐nine involved peripheral blood or bone marrow samples from 33 patients with SS and 19 patients with MF were studied by 10‐color flow cytometry, including CD62L, CD45RA, CCR4, and PD‐1. Gated tumor events were classified as naïve (TN), central memory (TCM), effector memory (TEM), or effector memory with reacquired CD45RA (TEMRA); based on CD62L+/CD45RA+, CD62L+/CD45RA−, CD62L−/CD45RA−, or CD62L−/CD45RA+ phenotype, respectively. Sequential specimens were compared to assess for phenotypic stability.ResultsThe naïve/memory phenotype of the neoplastic T‐cells was markedly heterogeneous, with a dominant TN, TCM, TEM, or TEMRA subset on 11 (14%), 32 (41%), 30 (38%), and 6 (8%) cases, respectively. There was no correlation between the diagnosis of MF or SS and putative cell of origin (P = 0.4). Overexpression of CCR4 and PD1 was observed in most cases, with higher intensity in SS compared to MF. The naïve/memory phenotype remained the same for 10 patients up to 273 days after the initial analysis; while on six patients, the naïve/memory phenotype was different from the original phenotype.ConclusionsBoth SS and MF can have phenotypic features of any of the major naïve/memory T‐cell subsets, which questions the current principle of “cell‐of‐origin” distinction between SS and MF. Phenotypic shifts within these subsets are common, suggesting a functional state rather than a cell‐of‐origin surrogate. © 2018 International Clinical Cytometry Society
Cardiac sarcoidosis: Case presentation and Review of the literature
Chamorro-Pareja, Natalia , Marin‐Acevedo, Julian A. , Chirilă, Răzvan M.

Mayo Clinic

Romanian Journal of Internal Medicine | October 17, 2018 | Volume: 57 | Issue: 1 | Pages: 7-13

10.2478/rjim-2018-0030 | PMID 30375351 Get It

Abstract Cardiac sarcoidosis usually occurs in the context of systemic disease; however, isolated cardiac involvement can occur in up to 25% of cases and tends to be clinically silent. When symptoms are present, they are often nonspecific and occasionally fatal, representing a diagnostic challenge. A high index of clinical suspicion and the integration of appropriate imaging, laboratory, and pathologic findings is always required. Treatment aims to control the systemic inflammatory condition while preventing further cardiac damage. However, even with adequate diagnosis and treatment strategies, prognosis remains poor. We describe the case of a patient who presented with cardiac symptoms, whose initial examination was unrevealing. Diagnosis was made retrospectively based on later systemic manifestations that revealed characteristic sarcoidosis findings.
Group 2 ITI Consensus Report: Prosthodontics and implant dentistry
Morton, Dean , Gallucci, German O. , Lin, Wei‐Shao , Pjetursson, Bjarni E. , Polido, Waldemar D. , Roehling, Stefan , Aghaloo, Tara , Albera, Hugo, Bohner, Lauren , Braut, Vedrana, Buser, Daniel , Dawson, Anthony S. , Eckert, Steven E, Gahlert, Michael, Hamilton, Adam , Jaffin, Robert A., Jarry, Christian , Laine, Juhani, Martin, William , Rahman, Lira, Schlegel, Andreas, Shiota, Makato, Stilwell, Charlotte , Vorster, Christiaan, Zembic, Anja , Zhou, Wenjie , Eckert, Steven, Sailer, Irena , Chen, Stephen , Karayazgan, Banu , Rahman, Lira

Mayo Clinic

Clinical Oral Implants Research | October 17, 2018 | Volume: 29 | Issue: S16 | Pages: 215-223

10.1111/clr.13298 | PMID 30328196 Get It

Abstract Objectives Working Group 2 was convened to address topics relevant to prosthodontics and dental implants. Systematic reviews were developed according to focused questions addressing (a) the number of implants required to support fixed full‐arch restorations, (b) the influence of intentionally tilted implants compared to axial positioned implants when supporting fixed dental prostheses ( FDP s), (c) implant placement and loading protocols, (d) zirconia dental implants, (e) zirconia and metal ceramic implant supported single crowns and (f) zirconia and metal ceramic implant supported FDP s. Materials and methods Group 2 considered and discussed information gathered in six systematic reviews. Group participants discussed statements developed by the authors and developed consensus. The group developed and found consensus for clinical recommendations based on both the statements and the experience of the group. The consensus statements and clinical recommendations were presented to the plenary (gathering of all conference attendees) and discussed. Final versions were developed after consensus was reached. Results A total of 27 consensus statements were developed from the systematic reviews. Additionally, the group developed 24 clinical recommendations based on the combined expertise of the participants and the developed consensus statements. Conclusions The literature supports the use of various implant numbers to support full‐arch fixed prostheses. The use of intentionally tilted dental implants is indicated when appropriate conditions exist. Implant placement and loading protocols should be considered together when planning and treating patients. One‐piece zirconia dental implants can be recommended when appropriate clinical conditions exist although two‐piece zirconia implants should be used with caution as a result of insufficient data. Clinical performance of zirconia and metal ceramic single implant supported crowns is similar and each demonstrates significant, though different, complications. Zirconia ceramic FDP s are less reliable than metal ceramic. Implant supported monolithic zirconia prostheses may be a future option with more supporting evidence.
Outcomes of Elbow Flexion Reconstruction in Patients Older than 50 with Traumatic Brachial Plexus Injury
Khouri, Joseph S., Kircher, Michelle F., Spinner, Robert J. , Gillis, Joshua A. , Bishop, Allen T. , Shin, Alexander Y.

Mayo Clinic

Plastic & Reconstructive Surgery | October 16, 2018 | Volume: 143 | Issue: 1 | Pages: 151-158

10.1097/prs.0000000000005094 | PMID 30325896 Get It

Background: There is controversy regarding the effectiveness of brachial plexus reconstruction for elbow function in older patients, as reported outcomes are generally poor. The purpose of this study was to evaluate elbow function outcomes in patients older than 50. Methods: Fifty-eight patients older than 50 years underwent nerve grafting, transfers, or free functioning muscle transfer to improve elbow function after traumatic brachial plexus injury. Patients were evaluated preoperatively and postoperatively for elbow flexion strength and range of motion; Disabilities of the Arm, Shoulder and Hand scores; pain; concomitant trauma; severity of trauma; and type of reconstruction. Results: The average age of the patients was 57.8 years, and the average follow-up was 24.0 months. The average modified British Medical Research Council elbow flexion grade improved significantly from 0.26 to 2.63. Thirty-three patients (60 percent) achieved functional flexion greater than or equal to M3 postoperatively, compared to zero patients preoperatively. There was no correlation between age and modified British Medical Research Council grade. Active elbow range of motion improved significantly postoperatively, with no effect of age on flexion motion. More patients achieved greater than or equal to M3 flexion with nerve transfers (69 percent) compared to free functioning muscle transfer (43 percent). Patients had worse outcomes with high-energy injuries. The mean Disabilities of the Arm, Shoulder and Hand score decreased from 51.5 to 49.6 postoperatively, and the average pain score decreased from 5.0 to 4.3. Conclusion: Brachial plexus reconstruction for elbow function in patients older than 50 can yield useful flexion. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.